secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001558370-23-011141
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine prices $125M public offering of 12.5M shares at $10.00/share
----------------------------------------------------------------------------

- Offering of 12,500,000 shares at $10.00 per share; gross proceeds ~$125 million.
- Underwriters granted 30-day option to purchase up to an additional 1,875,000 shares.
- Net proceeds estimated at ~$117.2 million, or ~$134.9 million if option fully exercised.
- Closing expected on or about June 20, 2023; J.P. Morgan, Cowen, and Evercore lead.
- Proceeds will support clinical-stage genome editing pipeline development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023011141/0001558370-23-011141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023011141/edit-20230614x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-011141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer